Celgene Corp (NASDAQ:CELG) - Share price - Overview

Stock Report

Celgene Corp CELG

Last Price
$136.31

Day Change
1.31|0.97%

As of 20/07/2017
19:46:37 EDT | USD
Minimum 15 Minutes Delay.

Last Close135.00
Day Range134.60 - 137.45
Mkt Cap106.40Bil
52-Wk Range96.93 - 137.45
Yield %-
ISINUS1510201049
Volume3,856,925
P/E51.24
P/S9.39
P/CF28.63

Share Price

Financials
201420152016
More ...
Income Statement
Revenue7,670.409,256.0011,229.20
Operating Income2,519.002,254.603,166.60
Net Income1,999.901,602.001,999.20
Basic EPS2.492.022.57
Avg. Diluted Shares Outstanding836825803
Balance Sheet
Current Assets9,712.609,400.9010,867.50
Non Current Assets7,627.5017,652.5017,218.10
Total Assets17,340.1027,053.4028,085.60
Current Liabilities2,112.201,968.902,959.20
Total Liabilities10,815.3021,134.4021,486.30
Total Equity6,524.805,919.006,599.30
Cash Flow
Operating Cash Flow2,806.302,483.903,976.30
Capital Expenditure-175.10-286.30-236.20
Free Cash Flow2,631.202,197.603,740.10

In millions, except "Basic EPS". Currency is USD.

Company Profile

Celgene Corp is a biotech company that discovers, develops, and commercializes therapies designed to treat cancer and immune-inflammatory related diseases. Its registered brands are Abraxane, Istodax, Otezla, Pomalyst, Revlimid, Thalomid, Vidaza.

Sector

Healthcare

Industry

Biotechnology

Stock Style

Large-Growth

Fiscal Year Ends

December

Employees

7,132
Key Stats
More ...
Price/Earning TTM49.09
Price/Book13.79
Price/Sales TTM9.30
Rev Growth (3 year avg)20.03
EPS Growth (3 year avg)-
Operating Margin % TTM28.20
Net Margin % TTM17.80
ROE TTM31.94
Debt/Equity2.09
Dividends
PreviousLatest
More ...
Declared Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2017 Morningstar. All rights reserved.